377 related articles for article (PubMed ID: 9565824)
61. Plasma folate but not vitamin B(12) or homocysteine concentrations are reduced after short-term vitamin B(6) supplementation.
Bosy-Westphal A; Holzapfel A; Czech N; Müller MJ
Ann Nutr Metab; 2001; 45(6):255-8. PubMed ID: 11786647
[TBL] [Abstract][Full Text] [Related]
62. Blood vitamin status (B1, B2, B6, folic acid and B12) in patients with alcoholic liver disease.
Majumdar SK; Shaw GK; O'Gorman P; Aps EJ; Offerman EL; Thomson AD
Int J Vitam Nutr Res; 1982; 52(3):266-71. PubMed ID: 7174224
[TBL] [Abstract][Full Text] [Related]
63. Folic acid--an innocuous means to reduce plasma homocysteine.
Brattström LE; Israelsson B; Jeppsson JO; Hultberg BL
Scand J Clin Lab Invest; 1988 May; 48(3):215-21. PubMed ID: 3375778
[TBL] [Abstract][Full Text] [Related]
64. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
Dierkes J; Westphal S; Kunstmann S; Banditt P; Lössner A; Luley C
Atherosclerosis; 2001 Sep; 158(1):161-4. PubMed ID: 11500187
[TBL] [Abstract][Full Text] [Related]
65. Theophylline increases pyridoxal kinase activity independently from vitamin B6 nutritional status.
Delport R; Ubbink JB; Vermaak WJ; Becker PJ
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):325-33. PubMed ID: 8480077
[TBL] [Abstract][Full Text] [Related]
66. The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis.
Pietrzik K; Brönstrup A
Arch Latinoam Nutr; 1997 Jun; 47(2 Suppl 1):9-12. PubMed ID: 9659410
[TBL] [Abstract][Full Text] [Related]
67. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction.
Constans J; Blann AD; Resplandy F; Parrot F; Renard M; Seigneur M; Guérin V; Boisseau M; Conri C
Br J Haematol; 1999 Dec; 107(4):776-8. PubMed ID: 10606884
[TBL] [Abstract][Full Text] [Related]
68. Homocysteine and oxidative stress in Egyptian children with Down syndrome.
Meguid NA; Dardir AA; El-Sayed EM; Ahmed HH; Hashish AF; Ezzat A
Clin Biochem; 2010 Aug; 43(12):963-7. PubMed ID: 20450901
[TBL] [Abstract][Full Text] [Related]
69. Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.
Taylor BV; Oudit GY; Evans M
Can Fam Physician; 2000 Nov; 46():2236-45. PubMed ID: 11143583
[TBL] [Abstract][Full Text] [Related]
70. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.
Folsom AR; Nieto FJ; McGovern PG; Tsai MY; Malinow MR; Eckfeldt JH; Hess DL; Davis CE
Circulation; 1998 Jul; 98(3):204-10. PubMed ID: 9697819
[TBL] [Abstract][Full Text] [Related]
71. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment.
Schwaninger M; Ringleb P; Winter R; Kohl B; Fiehn W; Rieser PA; Walter-Sack I
Epilepsia; 1999 Mar; 40(3):345-50. PubMed ID: 10080517
[TBL] [Abstract][Full Text] [Related]
72. The effect of a subnormal dose of vitamin B6 on plasma lipid in the rat.
Harripersad R; Burger FJ
Int J Vitam Nutr Res; 1997; 67(2):95-101. PubMed ID: 9129251
[TBL] [Abstract][Full Text] [Related]
73. Impairments in pyridoxine-dependent sulphur amino acid metabolism are highly sensitive to the degree of vitamin B6 deficiency and repletion in the pig.
Zhang Z; Kebreab E; Jing M; Rodriguez-Lecompte JC; Kuehn R; Flintoft M; House JD
Animal; 2009 Jun; 3(6):826-37. PubMed ID: 22444769
[TBL] [Abstract][Full Text] [Related]
74. The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations.
van der Griend R; Biesma DH; Haas FJ; Faber JA; Duran M; Meuwissen OJ; Banga JD
J Intern Med; 2000 Sep; 248(3):223-9. PubMed ID: 10971789
[TBL] [Abstract][Full Text] [Related]
75. Homocysteine as a risk factor for atherosclerosis.
Temple ME; Luzier AB; Kazierad DJ
Ann Pharmacother; 2000 Jan; 34(1):57-65. PubMed ID: 10669187
[TBL] [Abstract][Full Text] [Related]
76. Homocysteine levels and cardiovascular disease.
Stampfer MJ
Am Fam Physician; 1997 Oct; 56(6):1568, 1571-2. PubMed ID: 9351424
[No Abstract] [Full Text] [Related]
77. [Homocysteine, a risk factor of atherosclerosis].
Ambrosi P; Rolland P; Garçon D
Arch Mal Coeur Vaiss; 1996 Dec; 89(12):1667-71. PubMed ID: 9137733
[TBL] [Abstract][Full Text] [Related]
78. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients.
Jungers P; Joly D; Massy Z; Chauveau P; Nguyen AT; Aupetit J; Chadefaux B
Nephrol Dial Transplant; 1999 Dec; 14(12):2903-6. PubMed ID: 10570095
[TBL] [Abstract][Full Text] [Related]
79. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients.
Arnadottir M; Brattström L; Simonsen O; Thysell H; Hultberg B; Andersson A; Nilsson-Ehle P
Clin Nephrol; 1993 Oct; 40(4):236-40. PubMed ID: 8261682
[TBL] [Abstract][Full Text] [Related]
80. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients.
Suliman ME; Divino Filho JC; Bàràny P; Anderstam B; Lindholm B; Bergström J
J Am Soc Nephrol; 1999 Jun; 10(6):1287-96. PubMed ID: 10361867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
